Methods are described for differentiating stem and post-natal cells into sex hormone-producing cells that can be administered to a patient autologously or allogeneically in order to maintain in balance, or rebalance, their hypothalamic-pituitary-gonadal (HPG) axis.

Methods are described for differentiating stem and post-natal cells into sex hormone-producing cells that can be administered to a patient autologously or allogeneically in order to maintain in balance, or rebalance, their hypothalamic-pituitary-gonadal (HPG) axis.

The present invention refers to field of assisted reproductive technologies, in particular to a sperm storage media, and describes mTOR enhancers, preferably the mTOR activator MHY 1485, as supplement for storage media, said supplemented media increasing sperm motility and viability during short-term room temperature storage, while sustaining the metabolic rates, without changing its fertilization potential (capacitation) and DNA integrity.

The present disclosure relates to compositions and methods for ablating epithelial cells, in particular to methods for ablating Sertoli cells in testis, and methods related thereto. In particular, the present disclosure relates to methods for ablating Sertoli and other cells in the testis using benzalkonium chloride, to methods for rescuing endogenous spermatogenesis in a subject suffering from Sertoli cell dysfunction, to methods of reconstructing spermatogenesis, to methods of treating infertility, and to methods for the selective depletion of epithelial cells in a tissue and for the treatment of diseases or disorders associated with damaged epithelial cells.

The present disclosure relates to compositions and methods for ablating epithelial cells, in particular to methods for ablating Sertoli cells in testis, and methods related thereto. In particular, the present disclosure relates to methods for ablating Sertoli and other cells in the testis using benzalkonium chloride, to methods for rescuing endogenous spermatogenesis in a subject suffering from Sertoli cell dysfunction, to methods of reconstructing spermatogenesis, to methods of treating infertility, and to methods for the selective depletion of epithelial cells in a tissue and for the treatment of diseases or disorders associated with damaged epithelial cells.

The subject matter described herein is directed to methods of producing decellularized and recellularized human prostate tissues and methods of treating disorders of a prostate, including BPH and prostate cancer, are disclosed. Prostate tissue engineering and the composition and construction of a prostate extracellular matrix (ECM) or a prostate tissue scaffold and interactions with its cellular components are also disclosed.

The subject matter described herein is directed to methods of producing decellularized and recellularized human prostate tissues and methods of treating disorders of a prostate, including BPH and prostate cancer, are disclosed. Prostate tissue engineering and the composition and construction of a prostate extracellular matrix (ECM) or a prostate tissue scaffold and interactions with its cellular components are also disclosed.

A method of improving integration and/or functionality of gonadal organoids introduced to a subject includes the steps of pre-treating the subject with a chorionic gonadotrophin (CG), administering a therapeutically effective amount of the gonadal organoids to the subject, and administering the CG to the subject over time post-treatment to maintain LHCG receptor expression and signaling.

A method of improving integration and/or functionality of gonadal organoids introduced to a subject includes the steps of pre-treating the subject with a chorionic gonadotrophin (CG), administering a therapeutically effective amount of the gonadal organoids to the subject, and administering the CG to the subject over time post-treatment to maintain LHCG receptor expression and signaling.

Provided are methods of in vitro maturation of spermatogonium by culturing the spermatogonium in a three-dimensional methylcellulose culture system (MCS) in a culture medium which comprises an effective concentration of a factor selected from the group consisting of granulocyte macrophages-colony stimulating factor (GM-CSF), interleukin-1 alpha (IL-1alpha), interleukin-1 beta (IL-1beta) and interleukin-6 (IL-6), under conditions capable of differentiating the spermatogonium into at least meiotic and/or postmeiotic cells, thereby in vitro maturing the spermatogonium.